Abstract Little is known about the vascular function and expression of endothelial and neuronal nitric oxide synthases (eNOS and nNOS) in Duchenne muscular dystrophy (DMD). Bradykinin is involved in the regulation of eNOS expression induced by angiotensin-converting enzyme inhibitors. We characterized the vascular function and eNOS and nNOS expression in a canine model of DMD and evaluated the effects of chronic bradykinin treatment. Vascular function was examined in conscious golden retriever muscular dystrophy (GRMD) dogs with left ventricular dysfunction (measured by echocardiography) and in isolated coronary arteries. eNOS and nNOS proteins in carotid arteries were measured by western blot and cyclic guanosine monophosphate (cGMP) content was analyzed by radioimmunoassay. Compared with controls, GRMD dogs had an impaired vasodilator response to acetylcholine. In isolated coronary artery, acetylcholineelicited relaxation was nearly absent in placebo-treated GRMD dogs. This was explained by reduced nNOS and eNOS proteins and cGMP content in arterial tissues.
Introduction
Duchenne muscular dystrophy (DMD) affects one in 3,500 male births, making it the most prevalent of muscular dystrophies. Mutations in the dystrophin gene located on the X chromosome (Xp21) lead to loss of sarcolemmal dystrophin [5, 20, 24] , disruption of dystrophin-glycoprotein complex and muscle damage. A selective loss of neuronal nitric oxide synthase (nNOS) in skeletal muscles contributes to muscle lesions in DMD [6, 8, 32] . In golden retriever muscular dystrophy (GRMD) dogs, a mutation in intron 6 of the dystrophin gene causes loss of dystrophin in striated muscles [13, 37] , resulting in severe muscle degeneration and ambulation disabilities [15, 31, 43] . GRMD dogs develop full spectrum of DMD pathology and clinical symptoms and are thought to be the most relevant DMD model for preclinical investigations [15, 31, 43] , including gene transfers [3, 7, 21] , cell therapy [15, 31] or pharmacologic therapy [42] . Similar to DMD patients, GRMD dogs also develop a dilated cardiomyopathy, a lethal cause for DMD patients [10, 42] . Although vascular endothelial dysfunction occurs in many pathological circumstances such as myocardial infarction-induced heart failure [14, 33] , little is known about vascular function in DMD patients as well as in GRMD dogs. A blister-like swelling of vascular endothelial cells was found in the biopsied muscle specimens from DMD patients at the preclinical stage [25] . This suggested that vascular endothelial dysfunction may occur in DMD patients, especially at a stage where cardiac function is impaired. In addition, in our preliminary experiments before infusion of placebo or bradykinin, acetylcholine induces smaller pressurelowering effect in GRMD dogs than in control normal dogs, suggesting vascular endothelial dysfunction in the formers. Therefore, our primary goal was to assess vascular function with a special focus on coronary endothelial function in GRMD dogs.
Bradykinin is an endogenous nonapeptide that exerts multiple functions in cardiovascular system. Physiologically, bradykinin exerts its actions through activation of B2 receptors leading to NO release [26, 39] . Bradykinin regulates human coronary vascular tone [18] and contributes to the improvement of systemic and coronary endothelial dysfunction during angiotensin-converting enzyme (ACE) inhibition [2, 30, 38] and to the cardioprotection of myocardial ischemia by preconditioning [12, 35] and by ACE inhibitors and angiotensin AT1 receptor blockers [17, 23, 44] . In dogs with tachycardia-induced dilated cardiomyopathy, endogenous bradykinin exerts a protective effect on cardiac function [9] while a bradykinin analogue improves left ventricular (LV) endocardial flow reserve [28] . In addition, chronic bradykinin infusion prevents the progression of heart failure by preserving LV diastolic and systolic functions and vascular endothelial function, which is probably related to a preserved endothelial NOS (eNOS) expression [41] . Moreover, bradykinin pathway seems to be involved in the upregulation of eNOS expression during ACE inhibition [1] . Thus, another goal of this research was to examine the effects of chronic bradykinin treatment on the vascular function and on the expression of eNOS and nNOS.
For these purposes, bradykinin was infused into the left atrium for 4 weeks at a dose without significant effect on arterial blood pressure [41] . To evaluate the vascular endothelial function, pressure-lowering effect of acetylcholine was examined in vivo before and after 4 weeks of treatment in conscious dogs and concentration-relaxation curves to acetylcholine were established in vitro on isolated circumflex coronary arteries. Since bradykinin stimulates the release of endothelium-derived vasodilator substances such as NO, prostacyclin and endothelium-derived hyperpolarizing factor (EDHF) [26] , acetylcholine-induced relaxation was examined in the absence or presence of Nx-nitro-L-arginine (LNA, a NOS inhibitor), indomethacin (a COX inhibitor), or LNA plus indomethacin combination. Because bradykinin exerts its actions essentially through NO [26] , the abundance of the two constitutively expressed NOS isoforms, eNOS and nNOS in the carotid artery was determined by western blot. Finally, because cGMP is the second messenger of NO [26, 34] , the cGMP content was measured in the carotid arteries of placebo-or bradykinintreated control and GRMD dogs.
Methods

Animals
The experiments were performed on dogs supplied by CEDS (Mézilles, France). The maintenance of animals, including postoperative care, analgesia and anti-infectious prophylaxis, was kept in accordance with the Guide for the care and Use of Laboratory animals (NIH publication No. 86-23, revised 1985) . The animals used in the present study were in common with a general study attempting to investigate cardiomyopathy features of GRMD dogs. Based on preliminary echocardiographic data obtained in three control dogs and eight GRMD dogs, we established criteria for the enrollment of GRMD dogs in the study: age C9 months and LV fractional shortening C25 and B35%. Accordingly, 14 GRMD dogs were included in the study and were instrumented with a catheter in the left atrium and another in the thoracic descending aorta during a left thoracotomy under general anesthesia induced with propofol (6.5 mg/kg, i.v.) and maintained with isoflurane (1-3% vol in 100% O 2 ). Preemptive and postoperative analgesia was ensured with morphine (0.1 mg/kg, i.v.) and a fentanyl patch (50 lg/h), respectively. Among them, three died of acute respiratory failure following food inhalation (n = 1), bronchopneumonia (n = 1) or gastric ulcers (n = 1) during postoperative recovery period, and one died of pulmonary hemorrhage associated with bronchopneumonia during the second week of infusion with 0.9% saline. Finally, we have obtained the results in ten GRMD dogs and eight age-matched normal dogs. After 2-3 weeks of postoperative recuperation, dogs were randomized into four groups: control placebo (n = 4), control bradykinin (n = 4), GRMD-placebo (n = 5) or GRMD-bradykinin (n = 5). After echocardiographic and hemodynamic studies at baseline, using a portable pump (Microject, Sorenson Medical) placed in a jacket attached on the back of the animal, a continuous infusion of 0.9% saline (166 ll/min) or bradykinin (1 lg/min, 166 ll/min corresponding to 46 ng/kg/min) was performed through the left atrial catheter for 4 weeks. This dose of bradykinin was shown to affect minimally arterial pressure by our previous study [41] .
At the time of killing, the coronary arteries were collected in ice-cold physiological saline solution for isolated vessel studies and the carotid arteries were collected and frozen with liquid nitrogen and stored at -80°C for biochemical study.
Echocardiography and in vivo vasodilator response to acetylcholine
At baseline, conventional echocardiography was performed in unsedated conscious dogs in standing position, using continuous ECG monitoring with a Vivid 7 ultrasound unit (General Electric Medical System, Waukesha, WI). LV diameter, LV free wall and interventricular septal wall thicknesses were measured at end-diastolic and end-systolic points. LV fractional shortening (%) was calculated as (LV end-diastolic diameter -LV end-systolic diameter)/ LV end-diastolic diameter 9 100%.
To evaluate in vivo vasodilator response, the effects of acetylcholine (0.3-3 lg/kg, i.v.) on arterial blood pressure measured by aortic catheter were recorded at baseline and after 4 weeks of placebo or bradykinin infusion in conscious control and GRMD dogs.
Study in isolated coronary arteries
To examine vascular function, the circumflex coronary artery freshly dissected from the heart was cleaned of adjacent connective tissue and cut into rings (&3 mm in length). All rings were suspended in isolated organ chambers for isometric tension recording. The organ chambers were filled with 20 ml of physiological saline solution (pH 7.4, at 37.4°C) containing (mM): 118.3 NaCl, 4.7 KCl, 2.5 CaCl 2 , 1.2 MgSO 4 , 1.2 KH 2 PO 4 , 25 NaHCO 3 , 0.016 EDTA and 11.1 glucose that was continuously gassed with 95% O 2 /5%CO 2 . The rings were equilibrated for 120 min under a resting tension of 2 g. During equilibration period, the rings were washed every 30 min. Then, a first relaxation to acetylcholine (Ach, 10 -4 M) was implemented to check the integrity of the endothelium in rings precontracted with the thromboxane A2 analogue, U46619 (10 -8 M). After rinsing with physiological saline solution to baseline tension, rings were equilibrated for 90 min. Thereafter, coronary artery rings were contracted with U46619 (10 -6 M). Each ring was randomly assigned to acetylcholine alone, acetylcholine ? indomethacin (3 9 10 -5 M), acetylcholine ? LNA (3 9 10 -5 M), or acetylcholine ? indomethacin (3 9 10 -5 M) ? LNA (3 9 10 -5 M). Responses to cumulative concentrations of acetylcholine (10 -10 to 10 -4 M) were then obtained. Relaxations were measured at the peak decrease in tension for each concentration of acetylcholine using IOX and Datanalyst softwares (EMKA Technologies, Paris, France). Results were expressed as percentage of the maximal tension induced by U46619.
Western blot
Frozen carotid arteries were grinded and then homogenized in buffer containing: 10 mM Tris-HCl pH 7.6, 250 mM sucrose inhibitors, 2 mM DTT, 20 mg/ml protease and 0.5% Igepal CA-630. The crude cell lysate was centrifuged for 15 min at 14,000 rpm. Protein concentration was determined with the Bio-Rad Protein Assay (Bio-Rad, France). Equal amounts of extracted proteins were separated on 4-15% SDS-PAGE gels and transferred to PVDF membranes using standard technique. Membranes were blocked with 6% milk in Tris buffered saline with Tween-20 for 1 h at room temperature. Then, membranes were incubated with rabbit polyclonal antibodies anti-NOS1 and anti-NOS3 (sc-8309 and sc-654, respectively, Santa-Cruz Biotechnology, USA) at a dilution of 1:200 and 1:400, respectively, for 1 h. After washing, membranes were incubated with HRP-Rabbit secondary antibody (1:5,000; Dako, France) for 30 min. Antibody-protein complexes were detected using an enhanced EZ-ECL chemiluminescent reagent (Biological Industries, Israel). Rabbit anticalnexin monoclonal antibody (1:5,000; Sigma, France) was used as a loading control. Densitometric analysis was performed using ImageJ software (NIH, USA).
Measurement of cyclic guanosine monophosphate
Because the coronary artery was used for the isolated vessel study, the measurement of cyclic guanosine monophosphate (cGMP) was performed in the carotid artery taken from the same dogs as the coronary artery. At the time of assay, frozen carotid segment (stored at -80°C) was homogenized and sonicated in medium containing acetate buffer (0.05 M, pH 5.8) and a phosphodiesterase inhibitor (3-isobutyl-1-1-methylxanthine, 0.1 mM). The homogenate was centrifuged (2,000g for 20 min at 4°C) and the supernatant used to determine the levels of cGMP by radioimmunoassay using the Amerlex method (Amersham, RPA525). The results are expressed in pmol per mg of total protein content.
Drugs used
Acetylcholine (Sigma), dissolved in H 2 O; bradykinin (NeoMPS, Strasbourg, France), dissolved in saline solution; LNA, Nx-nitro-L-arginine (Sigma), dissolved in H 2 O; indomethacin (Sigma), dissolved in DMSO; U46619, 9,11-dideoxy-11a,9a-epoxymethanoprostaglandin F 2a (Sigma), dissolved in methyl acetate.
Statistical analysis
Results are expressed as mean ± SEM. Statistical analysis was performed with StatView software (v5, Abacus Concepts Inc.). Nonparametric Kruskal-Wallis test was used to analyze the overall difference between the four groups. If there was a significant difference, the Mann-Whitney test was performed to identify differences between two mean values. When only two mean values were compared, the Mann-Whitney test was used. A p \ 0.05 was considered significant.
Results
Baseline characteristics of the control and GRMD dogs GRMD dogs had a smaller body weight (BW) than agematched control dogs (Table 1) , indicating an abnormal development of GRMD dogs. At baseline, GRMD dogs had significantly higher heart rate, lower systolic and mean arterial blood pressures than the control dogs and they presented an impaired LV contractile function indicated by a significantly reduced fractional shortening as compared with control dogs (Table 1) . LV end-diastolic diameter was slightly but not significantly smaller in GRMD dogs than control dogs. There was no difference for each parameter between the dogs randomized into placebo or bradykinin group for control dogs and for GRMD dogs.
Pressure-lowering effect of acetylcholine in GRMD dogs
In conscious control dogs, acetylcholine induced a dosedependent decrease in arterial blood pressure. This effect was significantly smaller in GRMD dogs than in control dogs (Fig. 1a) . After 4 weeks of infusion, the pressurelowering effects of acetylcholine in placebo-treated GRMD dogs remained smaller than in placebo-or bradykinintreated control dogs, whereas these effects in bradykinintreated GRMD dogs were significantly improved and were not statistically different from those in placebo-or bradykinin-treated control dogs (Fig. 1b) .
Impaired arterial endothelial function in GRMD dogs and its normalization by bradykinin treatment
One of the most important information issued from the isolated vessel study is that acetylcholine did not produce significant relaxation of the coronary arteries in placebotreated GRMD dogs (Fig. 2) , indicating an impaired vascular function in these animals. In contrast, acetylcholine relaxed precontracted coronary arteries in bradykinin-treated GRMD dogs to the same extent as in placebo-or bradykinin-treated control dogs (Fig. 2) , indicating a normalized vascular endothelial reactivity in bradykinintreated GRMD dogs. To determine the role of NO, vasodilator prostaglandins and EDHF in the effects of bradykinin, we examined the effect of acetylcholine in the presence of indomethacin, LNA or indomethacin plus LNA. In the coronary arteries of control dogs, acetylcholine-evoked relaxation was slightly decreased in the presence of indomethacin, suggesting a role of vasodilator prostaglandins. In contrast, the reduction was more pronounced in the presence of LNA, indicating a key role of NO in this setting (Fig. 3a) . There was a further inhibition in the presence of LNA plus indomethacin, suggesting also the role of vasodilator prostaglandins (Fig. 3a) . In coronary arteries of bradykinin-treated control dogs, relaxation response to acetylcholine was slightly reduced by indomethacin, but totally blunted by LNA or LNA plus indomethacin, indicating a more pronounced role of NO than vasodilator prostaglandins in this setting (Fig. 3b) . In coronary arteries of placebo-treated GRMD dogs, acetylcholine did not produce significant relaxation in the presence or absence of indomethacin, LNA or LNA plus indomethacin (Fig. 3c) . Differently, in the coronaries of bradykinin-treated GRMD dogs, acetylcholine-evoked relaxation was not modified by indomethacin, but was completely blocked by LNA or LNA plus indomethacin, indicating a crucial role of NO in this setting (Fig. 3d) . Thus, GRMD dogs had an impaired coronary endothelial function that was normalized by bradykinin through a NO-dependent mechanism. Expression of eNOS and nNOS proteins in the carotid artery
Compared to control dogs, eNOS protein levels were decreased in the carotid artery of placebo-treated GRMD dogs. In bradykinin-treated GRMD dogs, eNOS protein levels were significantly higher than in placebo-treated GRMD dogs and were similar to bradykinin-treated control dogs (Fig. 4a, b) , indicating an eNOS upregulation during bradykinin treatment. No significant difference for nNOS protein levels in the carotid artery was observed between placebo-or bradykinintreated control dogs (Fig. 4a, c) . In contrast, nNOS levels in the carotid artery were significantly reduced in placebotreated GRMD dogs (Fig. 4a, c) . nNOS levels in bradykinintreated GRMD dogs were not statistically different from those in bradykinin-treated control dogs but were higher than in placebo-treated GRMD dogs (Fig. 4a, c) .
Changes in cGMP content in the carotid artery in placebo-or bradykinin-treated GRMD dogs Compared with control dogs, the cGMP content in the carotid artery was significantly decreased in placebo-treated GRMD dogs (Fig. 5) . In contrast, the cGMP level was similar between the bradykinin-treated GRMD dogs and control dogs treated with placebo or bradykinin, indicating a restoration of cGMP level in bradykinin-treated GRMD dogs.
Discussion
Vascular endothelial dysfunction is associated with hypertension, diabetes, atherosclerosis, and heart failure. In DMD, pathological characteristics of skeletal muscles have been well recognized. In contrast, little information is available about vascular function in this disease. This study demonstrates that GRMD dogs with LV dysfunction had an impaired vascular response to acetylcholine both in terms of arterial blood pressure reduction in conscious state and relaxant response in isolated coronary arteries. It is known that endothelium-derived NO relaxes vascular smooth muscle cells and reduces vascular tone [27, 29] . An impaired endothelium-derived NO production related to reduced eNOS expression plays an important role in vascular dysfunction occurring in many cardiovascular disorders [16, 19, 29, 30, 34] . However, it remains unknown whether eNOS expression is changed in DMD patients. The second new finding of the present study is a reduced eNOS expression level in the carotid artery of GRMD dogs compared with control dogs, which should be at least partly responsible for impaired vascular endothelial function in these animals. On the other hand, previous studies have shown that nNOS is involved in the local regulation of blood flow in animals and in humans [4, 11, 22, 32, 36, 40] . In skeletal muscles of DMD patients, a selective loss of nNOS is associated with a reduced blood flow [32] . It was supposed that skeletal nNOS-derived NO opposes to a-adrenergic-mediated vasoconstriction to maintain blood flow in the exercising skeletal muscle. Its deficiency in skeletal muscles was thought to be related to abnormal vasoconstrictor responses to vasoactive agents in mdx or nNOS knockout mice [40] . Another new finding of the current study is that nNOS protein levels are also reduced in arterial vessels in dystrophin-deficiency myopathy, which might, along with reduced eNOS expression, contribute to altered endothelial function in GRMD dogs. The reduced cGMP content in the carotid artery further supports this hypothesis because cGMP is the common second messenger for both nNOS and eNOS.
Remarkably, in contrary to placebo-treated GRMD dogs, bradykinin-treated GRMD dogs exhibited a pressurelowering response to acetylcholine similar to that in placebo-or bradykinin-treated control dogs. The normalized relaxation response to acetylcholine was confirmed in isolated coronary arteries of bradykinin-treated GRMD dogs. This means that bradykinin treatment improved both coronary and systemic vascular function in GRMD dogs. Physiologically, bradykinin exerts its action through activation of G protein-coupled B2 receptors that increase the intracellular Ca 2? concentration by mobilizing Ca 2? from both intracellular and extracellular pools. The increase in cytosolic Ca 2? stimulates NOS to release NO and also contributes to the production of arachidonic acid. The latter can be further metabolized into prostacyclin by COX or into EDHF by cytochrome P450-dependent epoxygenase or monoxygenase [26] . Using LNA and indomethacin in isolated coronary artery rings, we found that acetylcholineevoked relaxation in bradykinin-treated GRMD dogs was essentially NO-mediated with a little role for prostacyclin or EDHF. This implies that coronary NO production was restored by bradykinin treatment. Although we did not measure e/nNOS protein levels in coronary tissues, this was supported by an upregulation of e/nNOS proteins and normalization of cGMP content in the carotid arteries of bradykinin-treated GRMD dogs. This study is the first one to demonstrate a significantly altered systemic and coronary vascular function in this model of DMD and to show a restoration of vascular endothelial reactivity by chronic bradykinin treatment through increasing eNOS and nNOS expression. This is of particular importance because of the fundamental role of NO in maintaining organ blood flow. An increased eNOS and nNOS expression renders vascular endothelial cells capable to increase NO production to induce vascular smooth muscle relaxation in response to various stimuli. Accordingly, we found similar cGMP levels in the carotid arteries of bradykinin-treated GRMD dogs and in bradykinin-treated control dogs. Although prostacyclin and EDHF may also participate in the bradykinin effects, the fact that indomethacin did not significantly affect the relaxation response to acetylcholine and that the combination of LNA and indomethacin completely blunted the relaxation response to acetylcholine in bradykinin-treated GRMD dogs suggests that the prostacyclin and EDHF pathways are not the major mechanisms involved in the beneficial effect of bradykinin on the vascular endothelial function in GRMD dogs.
In conclusion, our study is the first one to demonstrate that GRMD dogs with LV dysfunction presented a severe vascular dysfunction associated with a marked reduction in eNOS and nNOS expression and a reduced capacity to generate cGMP. Chronic bradykinin infusion restored vascular endothelial function through the NO-mediated mechanism. This was ensured by upregulation of eNOS and nNOS expression and by restoration of cGMP-generating capacity in the arterial vessels. Since the similarity in pathological changes and in origin of disease between GRMD and DMD, the results obtained in this canine model would have clinical relevance for the treatment of DMD.
